Thr214

Site Information
GNEALsPtsPFREGR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3204999

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	breast cancer ( 2 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 3 ) , Jurkat (T lymphocyte) ( 4 ) , SKBr3 (breast cell) ( 2 ) , Vero E6-S ('epithelial, kidney') ( 1 )

Upstream Regulation
Treatments:	BI_4834 ( 3 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
3	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
4	Possemato A (2010) CST Curation Set: 9643; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info